{"id":82,"date":"2023-06-27T06:03:03","date_gmt":"2023-06-27T06:03:03","guid":{"rendered":"https:\/\/www.itim-cj.ro\/PNCDI\/ket-in-pamam\/?page_id=82"},"modified":"2023-06-27T06:03:05","modified_gmt":"2023-06-27T06:03:05","slug":"rezumat","status":"publish","type":"page","link":"https:\/\/www.itim-cj.ro\/PNCDI\/ket-in-pamam\/rezumat\/","title":{"rendered":"Rezumat"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; use_background_color_gradient=&#8221;on&#8221; background_color_gradient_type=&#8221;elliptical&#8221; background_image=&#8221;https:\/\/www.itim-cj.ro\/PNCDI\/ket-in-pamam\/wp-content\/uploads\/2023\/06\/poza1.png&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_row _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_text _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; header_font=&#8221;|700|||||||&#8221; header_text_align=&#8221;center&#8221; header_text_color=&#8221;#FFFFFF&#8221; header_font_size=&#8221;42px&#8221; header_line_height=&#8221;2em&#8221; header_2_line_height=&#8221;2em&#8221; header_3_line_height=&#8221;2em&#8221; header_4_line_height=&#8221;2em&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;]<\/p>\n<h1>Rezumat proiect<\/h1>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_row _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_text _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;16px&#8221; header_line_height=&#8221;2em&#8221; header_2_line_height=&#8221;2em&#8221; header_3_line_height=&#8221;2em&#8221; header_4_line_height=&#8221;2em&#8221; custom_margin=&#8221;||||false|false&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p>Scopul proiectului const\u0103 \u00een consolidarea unei tinere echipe de cercetare, multidisciplinare, capabil\u0103 s\u0103 promoveze noi forme solide\/formul\u0103ri ale compusului farmaceutic activ antifungic Ketoconazol (KTZ) cu poten\u021bial de pia\u021b\u0103.<\/p>\n<p>Infec\u021biile fungice invazive (IFI) sunt o cauz\u0103 major\u0103 de morbiditate \u0219i mortalitate la prematuri, la pacien\u021bii imunocompromi\u0219i sau la cei cu sindrom de imunodeficien\u021b\u0103 dob\u00e2ndit\u0103. Estim\u0103ri recente sugereaz\u0103 c\u0103 IFI provoac\u0103 cel pu\u021bin la fel de multe decese ca malaria \u0219i tuberculoza. Agen\u021bii antifungici de tip azolici reprezint\u0103 medicamentele de baz\u0103 utilizate \u00een tratamentul clinic al infec\u021biilor fungice, KTZ fiind primul ingredient farmaceutic activ (API) antifungic oral cu spectru larg aprobat in SUA de FDA \u00een 1981.<\/p>\n<p>\u00a0Ketoconazol este un medicament de clasa II, cu solubilitate sc\u0103zut\u0103 \u0219i permeabilitate ridicat\u0103. Solubilitatea sa foarte sc\u0103zut\u0103 \u00een ap\u0103, 0,017 mg\/mL \u00eei limiteaz\u0103 biodisponibilitatea, deoarece este eliminat din tractul gastrointestinal \u00eenainte de a fi complet dizolvat, reduc\u00e2nd absorb\u021bia acestuia \u00een circula\u021bia sanguin\u0103. Astfel, ob\u021binerea de noi forme solide\/formul\u0103ri de Ketoconazol cu solubilitate \u0219i biodisponibilitate \u00eembun\u0103t\u0103\u021bit\u0103 poate constitui baza unui produs mai bun, cu scopul de a maximiza eficien\u021ba terapeutic\u0103 a medicamentului.<\/p>\n<p>\u00a0Experien\u021ba mea de cercetare \u00een dezvoltarea de noi forme solide de API va fi extins\u0103 cu cuno\u0219tin\u021be despre incapsularea API-dendrimer PAMAM, activitatea antifungic\u0103 \u0219i studii de biocompatibilitate.<\/p>\n<p>Echipa de cercetare va consolida poten\u021bialul de pia\u021b\u0103 pentru dou\u0103 noi co-cristale, KTZ-Acid Adipic \u0219i KTZ-Acid Sorbic, cu solubilitatea crescut\u0103, de 100, respectiv de 40 de ori mai mare fa\u021b\u0103 de KTZ comercial, precum \u0219i pentru complexul KTZ-PAMAM, ca \u0219i API-uri \u00een produse antifungice optimizate cu administrare oral\u0103\/topic\u0103. Pentru formele de tip co-cristal se vor completa informa\u021biile preliminare de preformulare cu studii\/evalu\u0103ri specifice: compatibilitatea cu excipien\u021bi farmaceutici, teste \u00een vitro \u0219i \u00een vivo de biocompatibilitate, un protocol pentru procesul de co-cristalizare la scar\u0103 de gram, necesar \u00een industria farmaceutic\u0103 pentru dezvoltarea unui proces de co-cristalizare industrial de succes.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rezumat proiectScopul proiectului const\u0103 \u00een consolidarea unei tinere echipe de cercetare, multidisciplinare, capabil\u0103 s\u0103 promoveze noi forme solide\/formul\u0103ri ale compusului farmaceutic activ antifungic Ketoconazol (KTZ) cu poten\u021bial de pia\u021b\u0103. Infec\u021biile fungice invazive (IFI) sunt o cauz\u0103 major\u0103 de morbiditate \u0219i mortalitate la prematuri, la pacien\u021bii imunocompromi\u0219i sau la cei cu sindrom de imunodeficien\u021b\u0103 dob\u00e2ndit\u0103. Estim\u0103ri [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-82","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.itim-cj.ro\/PNCDI\/ket-in-pamam\/wp-json\/wp\/v2\/pages\/82","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.itim-cj.ro\/PNCDI\/ket-in-pamam\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.itim-cj.ro\/PNCDI\/ket-in-pamam\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.itim-cj.ro\/PNCDI\/ket-in-pamam\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.itim-cj.ro\/PNCDI\/ket-in-pamam\/wp-json\/wp\/v2\/comments?post=82"}],"version-history":[{"count":2,"href":"https:\/\/www.itim-cj.ro\/PNCDI\/ket-in-pamam\/wp-json\/wp\/v2\/pages\/82\/revisions"}],"predecessor-version":[{"id":85,"href":"https:\/\/www.itim-cj.ro\/PNCDI\/ket-in-pamam\/wp-json\/wp\/v2\/pages\/82\/revisions\/85"}],"wp:attachment":[{"href":"https:\/\/www.itim-cj.ro\/PNCDI\/ket-in-pamam\/wp-json\/wp\/v2\/media?parent=82"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}